278 related articles for article (PubMed ID: 25187123)
1. Idelalisib: first global approval.
Markham A
Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
[TBL] [Abstract][Full Text] [Related]
2. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
Hewett YG; Uprety D; Shah BK
J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
9. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib approved for three blood cancers.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
[No Abstract] [Full Text] [Related]
16. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
17. Duvelisib: First Global Approval.
Blair HA
Drugs; 2018 Nov; 78(17):1847-1853. PubMed ID: 30430368
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.
Visentin A; Briani C; Imbergamo S; Frezzato F; Angelini A; Fedrigo M; Cacciavillani M; Altinier S; Piazza F; Semenzato G; Adami F; Trentin L
Hematol Oncol; 2018 Feb; 36(1):366-369. PubMed ID: 28971495
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]